Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frank Westermann

Showing results (61-70 of 134) with videos related to

Pageof 14
Sort By:
Translational Oncology|January 28, 2014
Testing of SNS-032 in a Panel of Human Neuroblastoma Cell Lines with Acquired Resistance to a Broad Range of DrugsNadine Löschmann, Martin Michaelis, Florian Rothweiler, et al.
Cancers|November 25, 2020
Identification of VRK1 as a New Neuroblastoma Tumor Progression Marker Regulating Cell ProliferationAna Colmenero-Repiso, María A Gómez-Muñoz, Ismael Rodríguez-Prieto, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 27, 2007
High Skp2 expression characterizes high-risk neuroblastomas independent of MYCN statusFrank Westermann, Kai-Oliver Henrich, Jun S Wei, et al.
Nature Cell Biology|February 23, 2010
miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasisLi Ma, Jennifer Young, Harsha Prabhala, et al.
Science Signaling|December 24, 2015
Signaling pathway models as biomarkers: Patient-specific simulations of JNK activity predict the survival of neuroblastoma patientsDirk Fey, Melinda Halasz, Daniel Dreidax, et al.
Molecular Oncology|November 25, 2015
Transcription factor activating protein 2 beta (TFAP2B) mediates noradrenergic neuronal differentiation in neuroblastomaFakhera Ikram, Sandra Ackermann, Yvonne Kahlert, et al.
BMC Genomics|September 24, 2004
cDNA array-CGH profiling identifies genomic alterations specific to stage and MYCN-amplification in neuroblastomaQing-Rong Chen, Sven Bilke, Jun S Wei, et al.
Life Science Alliance|July 31, 2023
Exploring the impact of dexamethasone on gene regulation in myeloma cellsVictor Bessonneau-Gaborit, Jonathan Cruard, Catherine Guerin-Charbonnel, et al.
Ebiomedicine|December 9, 2022
Inherited rare variants in homologous recombination and neurodevelopmental genes are associated with increased risk of neuroblastomaFerdinando Bonfiglio, Vito Alessandro Lasorsa, Sueva Cantalupo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 10, 2021
FOXR2 Stabilizes MYCN Protein and Identifies Non-<i>MYCN</i>-Amplified Neuroblastoma Patients With Unfavorable OutcomeFelix Schmitt-Hoffner, Sjoerd van Rijn, Umut H Toprak, et al.
Pageof 14

Showing results (61-70 of 134) with videos related to

Sort By:
Pageof 14
Translational Oncology|January 28, 2014
Testing of SNS-032 in a Panel of Human Neuroblastoma Cell Lines with Acquired Resistance to a Broad Range of DrugsNadine Löschmann, Martin Michaelis, Florian Rothweiler, et al.
Cancers|November 25, 2020
Identification of VRK1 as a New Neuroblastoma Tumor Progression Marker Regulating Cell ProliferationAna Colmenero-Repiso, María A Gómez-Muñoz, Ismael Rodríguez-Prieto, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 27, 2007
High Skp2 expression characterizes high-risk neuroblastomas independent of MYCN statusFrank Westermann, Kai-Oliver Henrich, Jun S Wei, et al.
Nature Cell Biology|February 23, 2010
miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasisLi Ma, Jennifer Young, Harsha Prabhala, et al.
Science Signaling|December 24, 2015
Signaling pathway models as biomarkers: Patient-specific simulations of JNK activity predict the survival of neuroblastoma patientsDirk Fey, Melinda Halasz, Daniel Dreidax, et al.
Molecular Oncology|November 25, 2015
Transcription factor activating protein 2 beta (TFAP2B) mediates noradrenergic neuronal differentiation in neuroblastomaFakhera Ikram, Sandra Ackermann, Yvonne Kahlert, et al.
BMC Genomics|September 24, 2004
cDNA array-CGH profiling identifies genomic alterations specific to stage and MYCN-amplification in neuroblastomaQing-Rong Chen, Sven Bilke, Jun S Wei, et al.
Life Science Alliance|July 31, 2023
Exploring the impact of dexamethasone on gene regulation in myeloma cellsVictor Bessonneau-Gaborit, Jonathan Cruard, Catherine Guerin-Charbonnel, et al.
Ebiomedicine|December 9, 2022
Inherited rare variants in homologous recombination and neurodevelopmental genes are associated with increased risk of neuroblastomaFerdinando Bonfiglio, Vito Alessandro Lasorsa, Sueva Cantalupo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 10, 2021
FOXR2 Stabilizes MYCN Protein and Identifies Non-<i>MYCN</i>-Amplified Neuroblastoma Patients With Unfavorable OutcomeFelix Schmitt-Hoffner, Sjoerd van Rijn, Umut H Toprak, et al.
Pageof 14